Array Biopharma (ARRY) Reports Smaller-Than-Expected Q3 Loss; CEO Comments on Potential Milestone Payments From Partners
Tweet Send to a Friend
Array Biopharma (Nasdaq: ARRY) reports a Q3 loss of $0.30, 4 cents better than the analyst estimate of ($0.34) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
